keyword
MENU ▼
Read by QxMD icon Read
search

Neuroendocrine cancer

keyword
https://www.readbyqxmd.com/read/29666783/development-of-neuroendocrine-prostate-cancers-by-the-ser-arg-repetitive-matrix-4-mediated-rna-splicing-network
#1
Ahn R Lee, Nicole Che, Jessica M Lovnicki, Xuesen Dong
While the use of next-generation androgen receptor pathway inhibition (ARPI) therapy has significantly increased the survival of patients with metastatic prostate adenocarcinoma (AdPC), several groups have reported a treatment-resistant mechanism, whereby cancer cells can become androgen receptor (AR) indifferent and gain a neuroendocrine (NE)-like phenotype. This subtype of castration-resistant prostate cancer has been termed "treatment-induced castration-resistant neuroendocrine prostate cancer" (CRPC-NE)...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29662560/impact-of-68-ga-dota-peptide-pet-ct-on-the-management-of-gastrointestinal-neuroendocrine-tumour-gi-net-malaysian-national-referral-centre-experience
#2
Teik Hin Tan, Ching Yeen Boey, Boon Nang Lee
Purpose: The National Cancer Institute is the only referral centre in Malaysia that provides 68 Ga-DOTA-peptide imaging. The purpose of this study is to determine the impact of 68 Ga-DOTA-peptide PET/CT on the management of gastrointestinal neuroendocrine tumours (GI-NET). Materials and Methods: A cross-sectional study was performed to review the impact of 68 Ga-DOTA-peptide (68 Ga-DOTATATE or 68 Ga-DOTATOC) PET/CT on patients with biopsy-proven GI-NET between January 2011 and December 2015...
April 2018: Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29659395/loss-of-psma-expression-in-non-neuroendocrine-dedifferentiated-acinar-prostate-cancer
#3
Peter Bronsert, Kathrin Reichel, Juri Ruf
The introduction of tracers targeting the prostate-specific membrane antigen (PSMA) has revolutionized PET imaging of acinar prostate adenocarcinoma. In general, an increasing PSMA expression is assumed with increasing dedifferentiation. Whereas loss of PSMA expression has been reported in case of neuroendocrine dedifferentiation, we present a patient with acinar prostate adenocarcinoma with a loss of PSMA expression after chemotherapy on PET/CT and in histological and immunohistochemical analyses. All tissue samples indicated the retention of acinar features but no expression of neuroendocrine markers (NSE, synaptophysin, chromogranin, and CD56), corresponding to nonelevated serum NSE...
April 13, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29655834/metformin-use-associates-with-longer-progression-free-survival-of-patients-with-diabetes-and-pancreatic-neuroendocrine-tumors-receiving-everolimus-and-or-somatostatin-analogues
#4
Sara Pusceddu, Claudio Vernieri, Massimo Di Maio, Riccardo Marconcini, Francesca Spada, Sara Massironi, Toni Ibrahim, Maria Pia Brizzi, Davide Campana, Antongiulio Faggiano, Dario Giuffrida, Maria Rinzivillo, Sara Cingarlini, Francesca Aroldi, Lorenzo Antonuzzo, Rossana Berardi, Laura Catena, Chiara De Divitiis, Paola Ermacora, Vittorio Perfetti, Annalisa Fontana, Paola Razzore, Carlo Carnaghi, Maria Vittoria Davì, Carolina Cauchi, Marilina Duro, Sergio Ricci, Nicola Fazio, Federica Cavalcoli, Alberto Bongiovanni, Anna La Salvia, Nicole Brighi, Annamaria Colao, Ivana Puliafito, Francesco Panzuto, Silvia Ortolani, Alberto Zaniboni, Francesco Di Costanzo, Mariangela Torniai, Emilio Bajetta, Salvatore Tafuto, Silvio Ken Garattini, Daniela Femia, Natalie Prinzi, Laura Concas, Giuseppe Lo Russo, Massimo Milione, Luca Giacomelli, Roberto Buzzoni, Gianfranco Delle Fave, Vincenzo Mazzaferro, Filippo de Braud
BACKGROUND & AIMS: Metformin seems to have anti-cancer effects. However, it is not clear whether use of glycemia and metformin affect outcomes of patients with advanced pancreatic neuroendocrine tumors (pNETs). We investigated the association between glycemia and progression-free survival (PFS) of patients with NETs treated with everolimus and/or somatostatin analogues, as well as the association between metformin use and PFS time. METHODS: We performed a retrospective analysis of 445 patients with advanced pNET treated at 24 medical centers in Italy, from 1999 through 2015...
April 12, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29629846/molecular-profiling-of-pancreatic-neuroendocrine-tumors-pnets-and-the-clinical-potential
#5
Massimiliano Camilli, Konstantinos Papadimitrio, Amanda Nogueira, Lorena Incorvaia, Antonio Galvano, Federica D'Antonio, Jose Ferri, Daniele Santini, Nicola Silvestris, Antonio Russo, Marc Peeters, Christian Rolfo
Pancreatic neuroendocrine tumors (pNETs) represent a small part of pancreatic neoplasms, and the knowledge about their indolent clinical course remains a subject of investigation. They occur sporadically or as part of familial cancer syndromes and are classified by WHO in 3 categories. There is ongoing research to understand their molecular profiling and leading mutations. Areas covered: The aim of this review is to clarify the overall aspects of tumorigenesis, to expose the latest developments in understanding the course of the disease and the possible therapeutic implications of these...
April 9, 2018: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29623910/evaluation-of-the-sharkcore-%C3%A2-needle-for-eus-guided-core-biopsy-of-pancreatic-neuroendocrine-tumors
#6
Benjamin L Witt, Rachel E Factor, Barbara E Chadwick, Justin Caron, Ali A Siddiqui, Douglas G Adler
Background and Objectives: EUS guided core biopsy was once rarely performed but is now entering mainstream practice. Neuroendocrine tumors often warrant core biopsy as sufficient tissue must be obtained to allow for special staining to ensure a correct diagnosis. Traditionally these lesions were sampled with FNA needles. We performed a retrospective pilot study to evaluate the clinical value and efficacy of the a new EUS core needle biopsy needle as compared to a standard EUS FNA needle in the evaluation of patients with known or suspected neuroendocrine tumors...
April 4, 2018: Endoscopic Ultrasound
https://www.readbyqxmd.com/read/29622795/antitumor-activity-of-cd56-chimeric-antigen-receptor-t-cells-in-neuroblastoma-and-sclc-models
#7
Denise L Crossland, Warren L Denning, Sonny Ang, Simon Olivares, Tiejuan Mi, Kirsten Switzer, Harjeet Singh, Helen Huls, Kate S Gold, Bonnie S Glisson, Laurence J Cooper, John V Heymach
The CD56 antigen (NCAM-1) is highly expressed on several malignancies with neuronal or neuroendocrine differentiation, including small-cell lung cancer and neuroblastoma, tumor types for which new therapeutic options are needed. We hypothesized that CD56-specific chimeric antigen receptor (CAR) T cells could target and eliminate CD56-positive malignancies. Sleeping Beauty transposon-generated CD56R-CAR T cells exhibited αβT-cell receptors, released antitumor cytokines upon co-culture with CD56+ tumor targets, demonstrated a lack of fratricide, and expression of cytolytic function in the presence of CD56+ stimulation...
April 6, 2018: Oncogene
https://www.readbyqxmd.com/read/29622373/antidepressants-appear-safe-in-patients-with-carcinoid-tumor-results-of-a-restrospective-review
#8
Elie Isenberg-Grzeda, Meredith MacGregor, Afton Bergel, Stacy Eagle, Fernando Espi-Forcen, Reema Mehta, Konstantina Matsoukas, Jonathan Wills, Diane Reidy-Lagunes, Yesne Alici
INTRODUCTION: Patients living with neuroendocrine tumors have high rates of depression, often necessitating antidepressants, including selective serotonin reuptake inhibitors (SSRI). Neuroendocrine tumors (NETs) secrete vasoactive substances, including serotonin, which contribute to the cluster of symptoms known as carcinoid syndrome (flushing and diarrhea). Controversy exists over whether or not antidepressants are safe in NET. We aimed to study the safety of antidepressant use in NET patients...
March 21, 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29620057/bladder-cancer-neuroendocrine-disease-genomics
#9
Clemens Thoma
No abstract text is available yet for this article.
April 5, 2018: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29618015/high-fear-of-disease-occurrence-is-associated-with-low-quality-of-life-in-patients-with-multiple-endocrine-neoplasia-type-1-men1-results-from-the-dutch-men1-study-group
#10
Rachel S van Leeuwaarde, Carolina R C Pieterman, Eveline M A Bleiker, Olaf M Dekkers, Anouk N van der Horst-Schrivers, Ad R Hermus, Wouter W de Herder, Madeleine L Drent, Peter H Bisschop, Bas Havekes, Menno R Vriens, Gerlof D Valk
Objective: Multiple Endocrine Neoplasia type 1 (MEN1) is a hereditary disease characterized by a high risk of developing primary hyperparathyroidism, duodenopancreatic neuroendocrine tumors (dpNETs) and pituitary tumors (PIT). Up to now, it is unclear if having MEN1 leads to psychological distress because of fear of disease occurrence (FDO), thereby potentially affecting quality of life. Design: A cross-sectional study was performed using the Dutch MEN1 cohort. All patients received the Cancer Worry Scale (score ≥ 14 reflecting high FDO), the SF-36 Health Related Quality of Life questionnaire (SF-36) and questions on sociodemographic and medical history...
March 30, 2018: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29613961/mr-imaging-of-thymic-epithelial-neoplasms
#11
Brett W Carter, John P Lichtenberger, Marcelo F Benveniste
Thymic epithelial neoplasms are malignant lesions that originate from the thymus and include thymoma, thymic carcinoma, and thymic neuroendocrine tumors. Although computed tomography (CT) is typically considered the imaging modality of choice for identifying thymic tumors, characterizing the primary neoplasm, and staging of disease, the role of magnetic resonance (MR) imaging continues to expand. MR imaging is effective in distinguishing thymic epithelial neoplasms and other malignant tumors from benign lesions in the prevascular mediastinum, can be used to characterize and stage thymic tumors in those patients with contraindications to contrast-enhanced CT, and can reveal morphologic features of thymic tumors...
April 2018: Topics in Magnetic Resonance Imaging: TMRI
https://www.readbyqxmd.com/read/29610395/the-future-of-cancer-treatment-using-precision-oncogenomics
#12
Lukas D Wartman
Clinicians should soon have the opportunity to use precision oncogenomics to tailor the optimal cancer treatment to a specific patient. Precision oncogenomics will incorporate different sequencing platforms depending on the goal of the sequencing result. For example, the sequencing strategy used in immuno-oncology for the design of a tumor-specific vaccine may be different than that used by oncologists following a patient for clearance of mutations from circulating tumor DNA in the peripheral blood. I will provide a broad overview of several of the ways that precision oncogenomics is likely to influence the field of oncology over the next several years building off the experience at the Genomics Tumor Board at Washington University in St...
April 2018: Cold Spring Harbor Molecular Case Studies
https://www.readbyqxmd.com/read/29606348/gkap-acts-as-a-genetic-modulator-of-nmdar-signaling-to-govern-invasive-tumor-growth
#13
Leanne Li, Qiqun Zeng, Arjun Bhutkar, José A Galván, Eva Karamitopoulou, Daan Noordermeer, Mei-Wen Peng, Alessandra Piersigilli, Aurel Perren, Inti Zlobec, Hugh Robinson, M Luisa Iruela-Arispe, Douglas Hanahan
Genetic linkage analysis previously suggested that GKAP, a scaffold protein of the N-methyl-D-aspartate receptor (NMDAR), was a potential modifier of invasion in a mouse model of pancreatic neuroendocrine tumor (PanNET). Here, we establish that GKAP governs invasive growth and treatment response to NMDAR inhibitors of PanNET via its pivotal role in regulating NMDAR pathway activity. Combining genetic knockdown of GKAP and pharmacological inhibition of NMDAR, we implicate as downstream effectors FMRP and HSF1, which along with GKAP demonstrably support invasiveness of PanNET and pancreatic ductal adenocarcinoma cancer cells...
March 9, 2018: Cancer Cell
https://www.readbyqxmd.com/read/29605035/the-efficacy-of-chemotherapy-and-operation-in-patients-with-colorectal-neuroendocrine-carcinoma
#14
Zhonghua Wu, Dehao Yu, Shan Zhao, Peng Gao, Yongxi Song, Yu Sun, Xiaowan Chen, Zhenning Wang
BACKGROUND: Colorectal neuroendocrine carcinoma (CRNEC) is a rare type of malignancy and is quite aggressive with dismal prognosis. Neither large-scale retrospective studies nor prospective studies have been performed to evaluate the prognostic value of adjuvant chemotherapy in patients with CRNEC. METHODS: Using the Surveillance, Epidemiology, and End Results-Medicare database, 318 elderly patients who were diagnosed with high-grade colorectal neuroendocrine tumors were included...
May 2018: Journal of Surgical Research
https://www.readbyqxmd.com/read/29600194/function-of-tumor-suppressors-in-resistance-to-antiandrogen-therapy-and-luminal-epithelial-plasticity-of-aggressive-variant-neuroendocrine-prostate-cancers
#15
REVIEW
Rama Soundararajan, Ana M Aparicio, Christopher J Logothetis, Sendurai A Mani, Sankar N Maity
Combined loss of tumor suppressors (TSPs), PTEN, TP53, and RB1, is highly associated with small cell carcinoma of prostate phenotype. Recent genomic studies of human tumors as well as analyses in mouse genetic models have revealed a unique role for these TSPs in dictating epithelial lineage plasticity-a phenomenon that plays a critical role in the development of aggressive variant prostate cancer (PCa) and associated androgen therapy resistance. Here, we summarize recently published key observations on this topic and hypothesize a possible mechanism by which concurrent loss of TSPs could potentially regulate the PCa disease phenotype...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29595759/multimodal-management-of-locally-advanced-neuroendocrine-cervical-carcinoma-a-single-institution-experience
#16
Pauline Castelnau-Marchand, Patricia Pautier, Catherine Genestie, Alexandra Leary, Enrica Bentivegna, Sébastien Gouy, Jean-Yves Scoazec, Philippe Morice, Christine Haie-Meder, Cyrus Chargari
OBJECTIVE: The aim of this study was to report our institutional experience of a multimodal approach for treatment of locally advanced high-grade neuroendocrine cervical cancer. METHODS AND MATERIALS: Patients with primary locally advanced neuroendocrine cervical cancer diagnosed between 2001 and 2014 were included. The scheduled treatment sequence was as follows: pelvic +/- para-aortic radiotherapy (according to tumor stage), associated with chemotherapy based on platine-derivate and etoposide regimen, followed with a brachytherapy boost, then completion surgery if there was no progression +/- consolidation etoposide chemotherapy (for a total of 5-6 cycles)...
March 27, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29594486/perceptions-of-care-and-patient-reported-outcomes-in-people-living-with-neuroendocrine-tumours
#17
Vanessa L Beesley, Matthew Burge, Monica Dumbrava, Jack Callum, Rachel E Neale, David K Wyld
BACKGROUND: Neuroendocrine tumours (NETs) are rare, and when metastatic NETs are incurable, the tumours are frequently slowly growing. Patients may be confronted with disease-specific problems and distinct issues when accessing health-care. We aimed to assess perceptions of care coordination, identify unmet needs, and examine if these varied by whether patients received specialist oncology care in a single hospital or shared between that and another hospital. We also quantified anxiety, depression, and NET-related physical symptoms...
March 29, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29594354/detection-of-the-merkel-cell-polyomavirus-in-the-neuroendocrine-component-of-combined-merkel-cell-carcinoma
#18
Thibault Kervarrec, Mahtab Samimi, Pauline Gaboriaud, Tarik Gheit, Agnès Beby-Defaux, Roland Houben, David Schrama, Gaëlle Fromont, Massimo Tommasino, Yannick Le Corre, Eva Hainaut-Wierzbicka, Francois Aubin, Guido Bens, Hervé Maillard, Adeline Furudoï, Patrick Michenet, Antoine Touzé, Serge Guyétant
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin. The main etiological agent is Merkel cell polyomavirus (MCPyV), detected in 80% of cases. About 5% of cases, called combined MCC, feature an admixture of neuroendocrine and non-neuroendocrine tumor cells. Reports of the presence or absence of MCPyV in combined MCC are conflicting, most favoring the absence, which suggests that combined MCC might have independent etiological factors and pathogenesis. These discrepancies might occur with the use of different virus identification assays, with different sensitivities...
March 28, 2018: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/29590641/gastroenteropancreatic-neuroendocrine-neoplasms-genes-therapies-and-models
#19
REVIEW
Kenta Kawasaki, Masayuki Fujii, Toshiro Sato
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) refer to a group of heterogeneous cancers of neuroendocrine cell phenotype that mainly fall into one of two subtypes: gastroenteropancreatic neuroendocrine tumors (GEP-NETs; well differentiated) or gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs; poorly differentiated). Although originally defined as orphan cancers, their steadily increasing incidence highlights the need to better understand their etiology. Accumulating epidemiological and clinical data have shed light on the pathological characteristics of these diseases...
February 26, 2018: Disease Models & Mechanisms
https://www.readbyqxmd.com/read/29581877/immune-checkpoint-inhibitors-in-large-cell-neuroendocrine-carcinoma-current-status
#20
Aman Chauhan, Susanne M Arnold, Jill Kolesar, Hala Elnakat Thomas, Mark Evers, Lowell Anthony
Introduction: Large cell neuroendocrine carcinomas (LCNEC) are a group of rare high grade neuroendocrine tumors that often behave clinically like small cell carcinoma (SCLC) and are treated as such. No major advancement in the management of these tumors has occurred in the last 30 years. Methods: We present a case series of three cases from Markey Cancer center along with a review of 13 published cases in the literature wherein immune-checkpoint inhibitors were utilized in the management of LCNEC...
March 6, 2018: Oncotarget
keyword
keyword
44160
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"